Skip to main content

Table 2 Clinical trials of ASI in advanced CRC

From: Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

Ref Vaccine Adjuvant Route Patients CR+PR MR SD
[27] Anti-Id 3H1 i.c AH 23 0 0 NR
[28] CEA/HbsAg-CMV i.m HBsAg 17 0 0 0
[29] DC-CEA peptid i.v No 10 1 1 2
[30] ALVAC(CEA-B7.1) i.m ALVAC/B7.1 13 0 0 2
[31] DC-CEA peptid i.v No 7 0 0 1
[32] Auto-tumor i.d NDV 13 4 0 8
[33] DC-CEA peptid i.t No 10 0 0 2
[34] Virus CEA s.c GM-CSF\IL-2 11 0 0 NI
[35] Virus CEA i.d/s.c Tricom/GM-CSF 35 0 0 14
[36] DC-CEA peptid s.c No 7 0 0 2
[37] SART3 peptide s.c IFA 12 0 0 1
[38] DC-CEA transfected i.v+id IL-2 11 0 0 0
[39] DC-CEA peptid s.c+id Tricom 11 0 0 6
[40] DC + tumor RNA i.v KLH 15 0 0 0
[41] DC+MAGE3 peptide i.v No 3 0 1 0
[42] SART-IcK-CyB multi peptide s.c Montanideisa-51 10 0 1 1
[43] Survive peptide s.c No 17 0 1 3
[44] DC + CEA peptide s.c/i.d No 11 0 0 3
[45] ALVAC expressing CEA+B7.1 i.d B7.1 28 0 0 7
[46] Autologous hemoderivative s.c GM-CSF 50 0 0 26
[47] DC+allogeneic tumor cell lysate i.d No 17 0 0 4
[48] TroVax i.m MVA 17 0 0 5
[49] P53-SLP s.c No 10 0 0 4
[50] tumor lysate pulsed-Dc i.t THI 8 0 0 4
[51] Aex+GM-CSF s.c GM-CSF 20 0 1 1
[52] DC+MHC-I peptide i.d IFN-[r]/GM-CSF 11 0 0 0
[53] Glutaraldehyde-fixed HUVECs i.d No 3 0 0 0
[54] Xenogenic polyantigenic vaccine s.c IL-2 37 2 10 11
[55] Oncolytic poxvirus JX-594 PEIT GM-CSF 4 0 0 3
[56] MIDGE s.c d-SLIM 10 2 1 2
[57] ALVAC-p53 i.v ALVAC 16 0 0 1
[58] ONYX-015 adevirus i.v No 18 0 0 7
[59] TNFa AutoVaccIne i.m AH 33 2 0 7
[60] rF-CEA-TRICOM i.d B7.1 11 0 1 4
[61] CEA alt-plused DC iv No 7 0 0 1
[62] DC-CEA peptid i.t IL-4/GM-CSF 10 0 0 2
[63] Murine monoclonal CEA-antibody i.d AH 15 0 0 1
[64] Ep-CAM protein s.c MPL/GM-CSF 11 0 0 3
[65] Vaccine virus expressing CEA i.d/s.c No 20 0 0 2
[66] DC + CEA peptide i.v/i.d IL-2 11 0 0 0
[67] Antibody SCV 106 mimicking 17-1A s.c AH 21 0 0 0
[68] Autologous tumor s.c Fibroblasts/IL-2 10 0 0 1
[69] retroviral vector- IL-2 allogeneic tumor cells + IL-1a i.d DETOX/IL-1a 22 0 2 0
Total 43    656 11(1.68%) 19(2.9%) 141(21.49%)
  1. Abbreviations: Ref, reference□AH: aluminum hydroxide; NI, not identifiable; NR, not Reported; DC, dendritic cells□NDV, newcastle disease virus; IL, interleukin; ß-HCG, ß-human chorionic gonadotropin; THI,tetanustoxoidntigen/hepatitis B/influence matrix peptide; IFA, incompleteFreund's adjuvant.